Background: Natural extracts and compounds used in traditional home medicine are known for their safety and a variety of health promoting and therapeutic potentials. In contrast to the single molecule mediated targets, the combinational therapies are preferred for their multi-functional and limited toxic regimens and may be useful for disease therapeutics as well as to increase the quality of life during a variety of environmental stresses. Purpose: We aimed to combine the active ingredients of Chinese (Helicteres angustifolia) and Indian (Withania somnifera) ginsengs to develop a natural, efficient, and welfare combinatorial mixture with high anti-stress and glial differentiation potentials. Methods: Using cultured cells as a model system, we developed a combination of active ingredients of Chinese (Cucurbitacin B [Cuc]) and Indian (Withanone [Wi-N]) ginsengs. Eleven chemical models of environmental stresses were used. Cytotoxicity studies were performed using human skin fibroblast for anti-stress and rat glioma cells for glial differentiation effects. Results: We demonstrate that the novel combination of Cuc and Wi-N, CucWi-N, was non-toxic to normal cells. It caused stress protection in assays using normal human fibroblasts subjected to a variety of stresses. Of note, cells showed remarkable protection against oxidative and UV stresses and marked by decrease in DNA damage and reactive oxygen species. We examined and found the glial differentiation potential of CucWi-N in rat glioblastoma cells. CucWi-N clearly induced differentiation phenotype, well-marked with upregulation of GAP43, MAP2, and GFAP, which have been shown to play a key role in glial differentiation. Conclusion: These data demonstrate anti-stress and glial differentiation potential of CucWi-N (a novel combination of Cuc and Wi-N) that could be recruited in nutraceutical and pharmaceutical avenues and hence warrant further evaluation and mechanistic studies.

Keywords:
Cucurbitacin B, Withanone, Glial differentiation, Stress, Therapeutics
1.
Dong CM, Wang XL, Wang GM, Zhang WJ, Zhu L, Gao S, et al: A stress-induced cellular aging model with postnatal neural stem cells. Cell Death Dis 2014; 5:e1116.
2.
Saunders LR, Verdin E: Cell biology. Stress response and aging. Science 2009; 323: 1021–1022.
3.
Kumar A, Rinwa P, Kaur G, Machawal L: Stress: neurobiology, consequences and management. J Pharm Bioallied Sci 2013; 5: 91–97.
4.
Moreno-Smith M, Lutgendorf SK, Sood AK: Impact of stress on cancer metastasis. Future Oncol 2010; 6: 1863–1881.
5.
Prasad S, Gupta SC, Pandey MK, Tyagi AK, Deb L: Oxidative stress and cancer: advances and challenges. Oxid Med Cell Longev 2016; 2016: 5010423.
6.
You W, Henneberg M: Cancer incidence increasing globally: the role of relaxed natural selection. Evol Appl 2018; 11: 140–152.
7.
Hudu SA, Alshrari AS, Syahida A, Sekawi Z: Cell culture, technology: enhancing the culture of diagnosing human diseases. J Clin Diagn Res 2016; 10:DE01–DE05.
8.
Li L, Gao R, Yu Y, Kaul Z, Wang J, Kalra RS, et al: Tumor suppressor activity of miR-451: identification of CARF as a new target. Sci Rep 2018; 8: 375.
9.
Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O: Oxidative stress and antioxidant defense. World Allergy Organ J 2012; 5: 9–19.
10.
Chen W, Jia Z, Pan MH, Anandh Babu PV: Natural products for the prevention of oxidative stress-related diseases: mechanisms and strategies. Oxid Med Cell Longev 2016; 2016: 4628502.
11.
Zhang L, Li J, Zong L, Chen X, Chen K, Jiang Z, et al: Reactive oxygen species and targeted therapy for pancreatic cancer. Oxid Med Cell Longev 2016; 2016: 1616781.
12.
Carvalho AN, Firuzi O, Gama MJ, Horssen JV, Saso L: Oxidative stress and antioxidants in neurological diseases: Is there still hope? Curr Drug Targets 2017; 18: 705–718.
13.
Uttara B, Singh AV, Zamboni P, Mahajan RT: Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009; 7: 65–74.
14.
Groenendijk FH and Bernards R: Drug resistance to targeted therapies: deja vu all over again. Mol Oncol 2014; 8: 1067–1083.
15.
Hoelder S, Clarke PA, Workman P: Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 2012; 6: 155–176.
16.
Rajesh E, Sankari LS, Malathi L, Krupaa JR: Naturally occurring products in cancer therapy. J Pharm Bioallied Sci 2015; 7(suppl 1):S181–S183.
17.
Wang H, Khor TO, Shu L, Su ZY, Fuentes F, Lee JH, et al: Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med Chem 2012; 12: 1281–1305.
18.
Gao R, Shah N, Lee JS, Katiyar SP, Li L, Oh E, et al: Withanone-rich combination of Ashwagandha withanolides restricts metastasis and angiogenesis through hnRNP-K. Mol Cancer Ther 2014; 13: 2930–2940.
19.
Grover A, Priyandoko D, Gao R, Shandilya A, Widodo N, Bisaria VS, et al: Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence. Int J Biochem Cell Biol 2012; 44: 496–504.
20.
Konar A, Shah N, Singh R, Saxena N, Kaul SC, Wadhwa R, et al: Protective role of Ashwagandha leaf extract and its component withanone on scopolamine-induced changes in the brain and brain-derived cells. PLoS One 2011; 6:e27265.
21.
Shah N, Kataria H, Kaul SC, Ishii T, Kaur G, Wadhwa R: Effect of the alcoholic extract of Ashwagandha leaves and its components on proliferation, migration, and differentiation of glioblastoma cells: combinational approach for enhanced differentiation. Cancer Sci 2009; 100: 1740–1747.
22.
Shah N, Singh R, Sarangi U, Saxena N, Chaudhary A, Kaur G, et al: Combinations of Ashwagandha leaf extracts protect brain-derived cells against oxidative stress and induce differentiation. PLoS One 2015; 10:e0120554.
23.
Vaishnavi K, Saxena N, Shah N, Singh R, Manjunath K, Uthayakumar M, et al: Differential activities of the two closely related withanolides, Withaferin A and Withanone: bioinformatics and experimental evidences. PLoS One 2012; 7:e44419.
24.
Widodo N, Takagi Y, Shrestha BG, Ishii T, Kaul SC, Wadhwa R: Selective killing of cancer cells by leaf extract of Ashwagandha: components, activity and pathway analyses. Cancer Lett 2008; 262: 37–47.
25.
Yu Y, Katiyar SP, Sundar D, Kaul Z, Miyako E, Zhang Z, et al: Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences. Cell Death Dis 2017; 8:e2755.
26.
Priyandoko D, Ishii T, Kaul SC, Wadhwa R: Ashwagandha leaf derived withanone protects normal human cells against the toxicity of methoxyacetic acid, a major industrial metabolite. PLoS One 2011; 6:e19552.
27.
Widodo N, Shah N, Priyandoko D, Ishii T, Kaul SC, Wadhwa R: Deceleration of senescence in normal human fibroblasts by withanone extracted from ashwagandha leaves. J Gerontol A Biol Sci Med Sci 2009; 64: 1031–1038.
28.
Chaudhary A, Kalra RS, Huang C, Prakash J, Kaul SC, Wadhwa R: 2,3-Dihydro-3beta-methoxy Withaferin-A protects normal cells against stress: molecular evidence of its potent cytoprotective activity. J Nat Prod 2017; 80: 2756–2760.
29.
Li K, Yu Y, Sun S, Liu Y, Garg S, Kaul SC, et al: Functional characterisation of anticancer activity in the aqueous extract of Helicteres angustifolia L. Roots. PLoS One 2016; 11: e0152017.
30.
Garg S, Kaul SC, Wadhwa R: Cucurbitacin B and cancer intervention: chemistry, biology and mechanisms (Review). Int J Oncol 2018; 52: 19–37.
31.
Wadhwa R, Kaul SC, Ikawa Y, Sugimoto Y: Identification of a novel member of mouse hsp70 family. Its association with cellular mortal phenotype. J Biol Chem 1993; 268: 6615–6621.
32.
Kroschinsky F, Stolzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, et al: New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care 2017; 21: 89.
33.
Goodenberger ML, Jenkins RB: Genetics of adult glioma. Cancer Genet 2012; 205: 613–621.
34.
Jessen KR: Glial cells. Int J Biochem Cell Biol 2004; 36: 1861–1867.
35.
Yin D, Wakimoto N, Xing H, Lu D, Huynh T, Wang X, et al: Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 2008; 123: 1364–1375.
36.
Touihri-Barakati I, Kallech-Ziri O, Ayadi W, Kovacic H, Hanchi B, Hosni K, et al: Cucurbitacin B purified from Ecballium elaterium (L.) A. Rich from Tunisia inhibits α5β1 integrin-mediated adhesion, migration, proliferation of human glioblastoma cell line and angiogenesis. Eur J Pharmacol 2017; 797: 153–161.
37.
Clericuzio M, Mella M, Vita-Finzi P, Zema M, Vidari G: Cucurbitane triterpenoids from Leucopaxillus gentianeus. J Nat Prod 2004; 67: 1823–1828.
38.
Pandey A, Bani S, Dutt P, Kumar Satti N, Avtar Suri K, Nabi Qazi G: Multifunctional neuroprotective effect of Withanone, a compound from Withania somnifera roots in alleviating cognitive dysfunction. Cytokine 2018; 102: 211–221.
39.
Purushotham PM, Kim JM, Jo EK, Senthil K: Withanolides against TLR4-activated innate inflammatory signalling pathways: a comparative computational and experimental study. Phytother Res 2017; 31: 152–163.
40.
Joshi P, Misra L, Siddique AA, Srivastava M, Kumar S, Darokar MP: Epoxide group relationship with cytotoxicity in withanolide derivatives from Withania somnifera. Steroids 2014; 79: 19–27.
41.
Gautam A, Wadhwa R, Thakur MK: Involvement of hippocampal Arc in amnesia and its recovery by alcoholic extract of Ashwagandha leaves. Neurobiol Learn Mem 2013; 106: 177–184.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.